Metastatic Squamous Non Small Cell Lung Cancer clinical trials

Explore recruiting metastatic squamous non small cell lung cancer clinical trials.

Recruiting metastatic squamous non small cell lung cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Metastatic Squamous Non Small Cell Lung Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Italy, Czechia, Ireland, Germany, France, Spain +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer

Germany, Italy, Spain, France, Ireland, Greece +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lung cancer that cannot be completely cured.

Spain, France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Germany, Austria, Spain, France, Poland, Romania

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum-based Chemotherapy for the First-line Treatment of Patients with Metastatic Squamous Non-small Cell Lung Cancer Whose Tumors Express PD-L1 (ARTEMIDE-Lung02)

Netherlands, Italy, Belgium, Hungary, Germany, Spain +3 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Metastatic Squamous Non Small Cell Lung Cancer trials by city

Metastatic Squamous Non Small Cell Lung Cancer in Toronto Metastatic Squamous Non Small Cell Lung Cancer in Vancouver Metastatic Squamous Non Small Cell Lung Cancer in Montreal Metastatic Squamous Non Small Cell Lung Cancer in Calgary Metastatic Squamous Non Small Cell Lung Cancer in Edmonton Metastatic Squamous Non Small Cell Lung Cancer in Ottawa Metastatic Squamous Non Small Cell Lung Cancer in Winnipeg Metastatic Squamous Non Small Cell Lung Cancer in Quebec City Metastatic Squamous Non Small Cell Lung Cancer in Hamilton Metastatic Squamous Non Small Cell Lung Cancer in Kitchener Metastatic Squamous Non Small Cell Lung Cancer in London Metastatic Squamous Non Small Cell Lung Cancer in Halifax Metastatic Squamous Non Small Cell Lung Cancer in New York Metastatic Squamous Non Small Cell Lung Cancer in Los Angeles Metastatic Squamous Non Small Cell Lung Cancer in Chicago Metastatic Squamous Non Small Cell Lung Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease